Cencora HR Executive Announces Retirement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 15 2026
0mins
Cencora "announced that Silvana Battaglia, Executive Vice President and Chief Human Resources Officer, has announced she will retire from the company following a distinguished seven-year tenure. She will be succeeded by Samantha Hammock, who will join Cencora as Executive Vice President and CHRO, effective July 13, 2026."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COR
Wall Street analysts forecast COR stock price to rise
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 298.550
Low
400.00
Averages
415.38
High
440.00
Current: 298.550
Low
400.00
Averages
415.38
High
440.00
About COR
Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cencora to Release Q3 Fiscal 2026 Results on August 5, 2026
- Earnings Release Schedule: Cencora, Inc. plans to announce its Q3 Fiscal 2026 results on August 5, 2026, prior to NYSE trading, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The company will host a conference call at 8:30 a.m. ET on August 5, featuring CEO Robert P. Mauch and CFO Eva C. Boratto, enhancing engagement with investors.
- Webcast Access: Investors can join the live call via the company’s website, with a recommendation to log on 10 minutes early, demonstrating Cencora's emphasis on technology and investor experience.
- Replay Information: A replay of the call will be available on the company’s website approximately one hour after the event and will remain accessible for one year, ensuring that investors who cannot attend live can still access critical information.
See More
Amgen vs Iovance: Investment Comparison
- Amgen's Stability: In FY 2025, Amgen reported nearly $36.7 billion in revenue, a 9.9% increase year-over-year, with a net income of approximately $7.7 billion and a net margin of about 21%, showcasing its strong profitability and stability in the global market.
- Iovance's Rapid Growth: Iovance achieved approximately $263.5 million in revenue for FY 2025, marking a 60.6% increase, yet it reported a net loss of nearly $391 million, indicating its innovative potential in cancer treatment but highlighting its lack of profitability.
- Risk Comparison: Amgen faces risks from government pricing regulations and competition from biosimilars, while Iovance must navigate the complexities of manufacturing personalized therapies and uncertainties regarding market adoption, which could impact their future market performance.
- Valuation Differences: Amgen has a forward P/E ratio of 15.1, reflecting its value as a mature company, whereas Iovance, still unprofitable, has a P/S ratio of 5.4, indicating its high-risk investment profile in the early growth stage.
See More
Cardinal Health Continues Growth with Stock Price Surge
- Outstanding Stock Performance: Cardinal Health achieved a remarkable 74% stock price increase in 2025, followed by a 7.9% rise year-to-date in 2026, reflecting sustained investor confidence in its growth strategy, significantly outperforming peers McKesson and Cencora.
- Enhanced Profitability: In its fiscal Q3 2026 earnings report, the company reported a 35% EPS growth and raised its earnings guidance again, underscoring management's confidence in sustained operational momentum despite macro uncertainties and pricing pressures.
- Strong Specialty Pharmaceutical Business: Cardinal Health's Pharmaceutical and Specialty Solutions segment saw an 11% revenue increase to $56.1 billion and an 18% profit rise in Q3, with expectations for specialty sales to exceed $50 billion in fiscal 2026, indicating robust growth potential in the market.
- Rapid Expansion of New Businesses: The company's
See More
Successful Virtual Investor Conference Held
- Rich Conference Content: The Energy & Precious Metals Virtual Investor Summit held on June 16, 2026, brought together executives from leading companies to showcase their corporate strategies and operational updates, enhancing investor engagement.
- Investor Interaction Opportunities: Participating companies engaged directly with investors through live Q&A sessions and one-on-one meetings, with management meeting requests accepted post-event, further fostering investor relations.
- On-Demand Viewing: Presentations from the summit will be available for on-demand viewing 24/7 for 90 days, allowing investors and analysts to download relevant materials at their convenience, improving information accessibility.
- Advantages of Virtual Conferences: Virtual Investor Conferences provide an efficient platform for investor access, replicating all aspects of on-site meetings, which helps companies connect better with global investors and enhances the efficiency of investor communications.
See More
Agenda Released for Energy & Precious Metals Investor Summit
- Conference Agenda Announced: Virtual Investor Conferences has announced the Energy & Precious Metals Investor Summit scheduled for June 16, inviting individual and institutional investors, advisors, and analysts to engage directly with OTCQX, OTCQB, and OTCID companies.
- No Participation Fee: The event is free to attend, allowing participants to pre-register and run system checks to expedite their participation and receive updates, highlighting the emphasis on investor convenience.
- Diverse Opportunities: The summit will cover a range of topics from gold exploration to uranium development, battery materials, royalties, and phosphates, showcasing the breadth of opportunities available in the energy and resource sectors today.
- Real-Time Interactive Platform: Virtual Investor Conferences offers a real-time investor engagement solution designed to enhance the efficiency of connections between companies and investors, while also enriching presentations with dynamic video content.
See More
Energy & Precious Metals Investor Summit Scheduled for June 16
- Agenda Announcement: Virtual Investor Conferences has announced the Energy & Precious Metals Investor Summit scheduled for June 16, inviting individual and institutional investors, advisors, and analysts to explore market opportunities.
- Free Participation: The summit is free of charge, allowing investors to pre-register and run system checks to expedite participation and receive event updates, enhancing the overall investor experience.
- Diverse Company Presentations: The conference will feature a range of sectors from gold exploration to uranium development, battery materials, royalties, and phosphates, providing OTCQX, OTCQB, and OTCID companies a platform to communicate directly with investors.
- Enhanced Investor Engagement: Virtual Investor Conferences offers a real-time investor engagement solution designed to improve the efficiency of company-investor connections, facilitating one-on-one meeting arrangements and enhancing presentation effectiveness.
See More
Cencora to Release Q3 Fiscal 2026 Results on August 5, 2026
- Earnings Release Schedule: Cencora, Inc. plans to announce its Q3 Fiscal 2026 results on August 5, 2026, prior to NYSE trading, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The company will host a conference call at 8:30 a.m. ET on August 5, featuring CEO Robert P. Mauch and CFO Eva C. Boratto, enhancing engagement with investors.
- Webcast Access: Investors can join the live call via the company’s website, with a recommendation to log on 10 minutes early, demonstrating Cencora's emphasis on technology and investor experience.
- Replay Information: A replay of the call will be available on the company’s website approximately one hour after the event and will remain accessible for one year, ensuring that investors who cannot attend live can still access critical information.
See More
Amgen vs Iovance: Investment Comparison
- Amgen's Stability: In FY 2025, Amgen reported nearly $36.7 billion in revenue, a 9.9% increase year-over-year, with a net income of approximately $7.7 billion and a net margin of about 21%, showcasing its strong profitability and stability in the global market.
- Iovance's Rapid Growth: Iovance achieved approximately $263.5 million in revenue for FY 2025, marking a 60.6% increase, yet it reported a net loss of nearly $391 million, indicating its innovative potential in cancer treatment but highlighting its lack of profitability.
- Risk Comparison: Amgen faces risks from government pricing regulations and competition from biosimilars, while Iovance must navigate the complexities of manufacturing personalized therapies and uncertainties regarding market adoption, which could impact their future market performance.
- Valuation Differences: Amgen has a forward P/E ratio of 15.1, reflecting its value as a mature company, whereas Iovance, still unprofitable, has a P/S ratio of 5.4, indicating its high-risk investment profile in the early growth stage.
See More
Cardinal Health Continues Growth with Stock Price Surge
- Outstanding Stock Performance: Cardinal Health achieved a remarkable 74% stock price increase in 2025, followed by a 7.9% rise year-to-date in 2026, reflecting sustained investor confidence in its growth strategy, significantly outperforming peers McKesson and Cencora.
- Enhanced Profitability: In its fiscal Q3 2026 earnings report, the company reported a 35% EPS growth and raised its earnings guidance again, underscoring management's confidence in sustained operational momentum despite macro uncertainties and pricing pressures.
- Strong Specialty Pharmaceutical Business: Cardinal Health's Pharmaceutical and Specialty Solutions segment saw an 11% revenue increase to $56.1 billion and an 18% profit rise in Q3, with expectations for specialty sales to exceed $50 billion in fiscal 2026, indicating robust growth potential in the market.
- Rapid Expansion of New Businesses: The company's
See More
Successful Virtual Investor Conference Held
- Rich Conference Content: The Energy & Precious Metals Virtual Investor Summit held on June 16, 2026, brought together executives from leading companies to showcase their corporate strategies and operational updates, enhancing investor engagement.
- Investor Interaction Opportunities: Participating companies engaged directly with investors through live Q&A sessions and one-on-one meetings, with management meeting requests accepted post-event, further fostering investor relations.
- On-Demand Viewing: Presentations from the summit will be available for on-demand viewing 24/7 for 90 days, allowing investors and analysts to download relevant materials at their convenience, improving information accessibility.
- Advantages of Virtual Conferences: Virtual Investor Conferences provide an efficient platform for investor access, replicating all aspects of on-site meetings, which helps companies connect better with global investors and enhances the efficiency of investor communications.
See More
Agenda Released for Energy & Precious Metals Investor Summit
- Conference Agenda Announced: Virtual Investor Conferences has announced the Energy & Precious Metals Investor Summit scheduled for June 16, inviting individual and institutional investors, advisors, and analysts to engage directly with OTCQX, OTCQB, and OTCID companies.
- No Participation Fee: The event is free to attend, allowing participants to pre-register and run system checks to expedite their participation and receive updates, highlighting the emphasis on investor convenience.
- Diverse Opportunities: The summit will cover a range of topics from gold exploration to uranium development, battery materials, royalties, and phosphates, showcasing the breadth of opportunities available in the energy and resource sectors today.
- Real-Time Interactive Platform: Virtual Investor Conferences offers a real-time investor engagement solution designed to enhance the efficiency of connections between companies and investors, while also enriching presentations with dynamic video content.
See More
Energy & Precious Metals Investor Summit Scheduled for June 16
- Agenda Announcement: Virtual Investor Conferences has announced the Energy & Precious Metals Investor Summit scheduled for June 16, inviting individual and institutional investors, advisors, and analysts to explore market opportunities.
- Free Participation: The summit is free of charge, allowing investors to pre-register and run system checks to expedite participation and receive event updates, enhancing the overall investor experience.
- Diverse Company Presentations: The conference will feature a range of sectors from gold exploration to uranium development, battery materials, royalties, and phosphates, providing OTCQX, OTCQB, and OTCID companies a platform to communicate directly with investors.
- Enhanced Investor Engagement: Virtual Investor Conferences offers a real-time investor engagement solution designed to improve the efficiency of company-investor connections, facilitating one-on-one meeting arrangements and enhancing presentation effectiveness.
See More
